NVO - Novo Nordisk A/S
52.60 0.00 (0.00%)
After hours: 4:17PM EDT
| Previous close | 52.52 |
| Open | 52.70 |
| Bid | 52.59 x 800 |
| Ask | 52.60 x 800 |
| Day's range | 52.38 - 52.93 |
| 52-week range | 41.59 - 53.55 |
| Volume | 1,488,904 |
| Avg. volume | 1,429,123 |
| Market cap | 123.202B |
| Beta (3Y monthly) | 0.62 |
| PE ratio (TTM) | 21.36 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.25 (2.38%) |
| Ex-dividend date | 2019-03-22 |
| 1y target est | N/A |
- Zacks
PFE vs. NVO: Which Stock Is the Better Value Option?
PFE vs. NVO: Which Stock Is the Better Value Option?
- Zacks
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
- Zacks
Top Analyst Reports for Intel, Oracle & Novo Nordisk
Top Analyst Reports for Intel, Oracle & Novo Nordisk
- Zacks
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
- Zacks
bluebird Inks Genome Editing Research Deal With Novo Nordisk
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
- Zacks
Novo Nordisk Focuses on Pipeline Development Amid Competition
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
- Zacks
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
- Simply Wall St.
An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
- Zacks
SNY or NVO: Which Is the Better Value Stock Right Now?
SNY vs. NVO: Which Stock Is the Better Value Option?
- Zacks
Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
- Zacks
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
- Zacks
Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label
CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.
- Reuters - UK Focus
UPDATE 2-European shares log fifth week of gains, Novo Nordisk shines
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
- Reuters
With a backup to the backup, insulin makers say they're primed for Brexit
For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.
- Reuters
Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Motley Fool
2 Stocks to Watch in September
These two businesses could receive a big boost this month if certain events fall in their favor.
- Zacks
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
- Simply Wall St.
We Think Novo Nordisk (CPH:NOVO B) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Zacks
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
- Zacks
Gilead & Galapagos Close Research & Development Agreement
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
- Zacks
Novo Nordisk (NVO) Is Up 2.77% in One Week: What You Should Know
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
